86 related articles for article (PubMed ID: 27998073)
1. Matrix Metalloproteinase Responsive Nanoparticles for Synergistic Treatment of Colorectal Cancer via Simultaneous Anti-Angiogenesis and Chemotherapy.
Shi L; Hu Y; Lin A; Ma C; Zhang C; Su Y; Zhou L; Niu Y; Zhu X
Bioconjug Chem; 2016 Dec; 27(12):2943-2953. PubMed ID: 27998073
[TBL] [Abstract][Full Text] [Related]
2. Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer.
Zhang WJ; Li Y; Wei MN; Chen Y; Qiu JG; Jiang QW; Yang Y; Zheng DW; Qin WM; Huang JR; Wang K; Zhang WJ; Wang YJ; Yang DH; Chen ZS; Shi Z
Cancer Lett; 2017 Feb; 386():100-109. PubMed ID: 27864115
[TBL] [Abstract][Full Text] [Related]
3. The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
García-Alfonso P; Grande E; Polo E; Afonso R; Reina JJ; Jorge M; Campos JM; Martínez V; Angeles C; Montagut C
Angiogenesis; 2014 Oct; 17(4):805-21. PubMed ID: 24793846
[TBL] [Abstract][Full Text] [Related]
4. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.
Yao M; Kargman S; Lam EC; Kelly CR; Zheng Y; Luk P; Kwong E; Evans JF; Wolfe MM
Cancer Res; 2003 Feb; 63(3):586-92. PubMed ID: 12566300
[TBL] [Abstract][Full Text] [Related]
6. Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer.
Yao M; Zhou W; Sangha S; Albert A; Chang AJ; Liu TC; Wolfe MM
Clin Cancer Res; 2005 Feb; 11(4):1618-28. PubMed ID: 15746067
[TBL] [Abstract][Full Text] [Related]
7. Tumor-targeting and microenvironment-responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis.
Huang S; Shao K; Liu Y; Kuang Y; Li J; An S; Guo Y; Ma H; Jiang C
ACS Nano; 2013 Mar; 7(3):2860-71. PubMed ID: 23451830
[TBL] [Abstract][Full Text] [Related]
8. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
Martinelli E; Troiani T; Morgillo F; Rodolico G; Vitagliano D; Morelli MP; Tuccillo C; Vecchione L; Capasso A; Orditura M; De Vita F; Eckhardt SG; Santoro M; Berrino L; Ciardiello F
Clin Cancer Res; 2010 Oct; 16(20):4990-5001. PubMed ID: 20810384
[TBL] [Abstract][Full Text] [Related]
9. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
[TBL] [Abstract][Full Text] [Related]
10. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
Locatelli SL; Giacomini A; Guidetti A; Cleris L; Mortarini R; Anichini A; Gianni AM; Carlo-Stella C
Leukemia; 2013 Aug; 27(8):1677-87. PubMed ID: 23360848
[TBL] [Abstract][Full Text] [Related]
11. Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.
Napolitano S; Martini G; Rinaldi B; Martinelli E; Donniacuo M; Berrino L; Vitagliano D; Morgillo F; Barra G; De Palma R; Merolla F; Ciardiello F; Troiani T
Clin Cancer Res; 2015 Jul; 21(13):2975-83. PubMed ID: 25838391
[TBL] [Abstract][Full Text] [Related]
12. Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model.
Denorme M; Yon L; Roux C; Gonzalez BJ; Baudin E; Anouar Y; Dubessy C
Cancer Lett; 2014 Oct; 352(2):236-44. PubMed ID: 25016061
[TBL] [Abstract][Full Text] [Related]
13. SN38 polymeric nanoparticles: in vitro cytotoxicity and in vivo antitumor efficacy in xenograft balb/c model with breast cancer versus irinotecan.
Sepehri N; Rouhani H; Tavassolian F; Montazeri H; Khoshayand MR; Ghahremani MH; Ostad SN; Atyabi F; Dinarvand R
Int J Pharm; 2014 Aug; 471(1-2):485-97. PubMed ID: 24879937
[TBL] [Abstract][Full Text] [Related]
14. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
15. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K
Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037
[TBL] [Abstract][Full Text] [Related]
16. The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.
Pignochino Y; Dell'Aglio C; Inghilleri S; Zorzetto M; Basiricò M; Capozzi F; Canta M; Piloni D; Cemmi F; Sangiolo D; Gammaitoni L; Soster M; Marchiò S; Pozzi E; Morbini P; Luisetti M; Aglietta M; Grignani G; Stella GM
BMC Cancer; 2015 May; 15():374. PubMed ID: 25952930
[TBL] [Abstract][Full Text] [Related]
17. Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo.
Zhang H; Li Z; Wang K
Oncol Rep; 2014 Apr; 31(4):1954-60. PubMed ID: 24549815
[TBL] [Abstract][Full Text] [Related]
18. The anti-metastatic effect of baicalein on colorectal cancer.
Chai Y; Xu J; Yan B
Oncol Rep; 2017 Apr; 37(4):2317-2323. PubMed ID: 28259937
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib and thyroid cancer.
Fallahi P; Ferrari SM; Santini F; Corrado A; Materazzi G; Ulisse S; Miccoli P; Antonelli A
BioDrugs; 2013 Dec; 27(6):615-28. PubMed ID: 23818056
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model.
Gremonprez F; Descamps B; Izmer A; Vanhove C; Vanhaecke F; De Wever O; Ceelen W
Oncotarget; 2015 Oct; 6(30):29889-900. PubMed ID: 26375674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
